CervoMed (CRVO) Competitors $1.94 0.00 (0.00%) (As of 10:32 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CRVO vs. OMGA, CDIO, BIVI, ACAB, ALRN, VIRI, ICCC, DYAI, PASG, and ESLAShould you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Omega Therapeutics (OMGA), Cardio Diagnostics (CDIO), BioVie (BIVI), Atlantic Coastal Acquisition Corp. II (ACAB), Aileron Therapeutics (ALRN), Virios Therapeutics (VIRI), ImmuCell (ICCC), Dyadic International (DYAI), Passage Bio (PASG), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. CervoMed vs. Omega Therapeutics Cardio Diagnostics BioVie Atlantic Coastal Acquisition Corp. II Aileron Therapeutics Virios Therapeutics ImmuCell Dyadic International Passage Bio Estrella Immunopharma Omega Therapeutics (NASDAQ:OMGA) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Is OMGA or CRVO more profitable? CervoMed has a net margin of -118.68% compared to Omega Therapeutics' net margin of -902.93%. CervoMed's return on equity of -44.11% beat Omega Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Omega Therapeutics-902.93% -213.13% -41.24% CervoMed -118.68%-44.11%-39.81% Does the MarketBeat Community believe in OMGA or CRVO? Omega Therapeutics received 15 more outperform votes than CervoMed when rated by MarketBeat users. Likewise, 73.68% of users gave Omega Therapeutics an outperform vote while only 72.22% of users gave CervoMed an outperform vote. CompanyUnderperformOutperformOmega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% CervoMedOutperform Votes1372.22% Underperform Votes527.78% Which has stronger valuation & earnings, OMGA or CRVO? CervoMed has higher revenue and earnings than Omega Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmega Therapeutics$3.09M15.36-$97.43M-$1.33-0.64CervoMed$7.14M1.68-$2.17MN/AN/A Do analysts recommend OMGA or CRVO? Omega Therapeutics presently has a consensus target price of $9.20, indicating a potential upside of 973.01%. CervoMed has a consensus target price of $42.00, indicating a potential upside of 2,064.95%. Given CervoMed's higher possible upside, analysts plainly believe CervoMed is more favorable than Omega Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80CervoMed 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.44 Does the media prefer OMGA or CRVO? In the previous week, CervoMed had 26 more articles in the media than Omega Therapeutics. MarketBeat recorded 26 mentions for CervoMed and 0 mentions for Omega Therapeutics. Omega Therapeutics' average media sentiment score of 1.89 beat CervoMed's score of 0.06 indicating that Omega Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Omega Therapeutics Very Positive CervoMed Neutral Which has more risk and volatility, OMGA or CRVO? Omega Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Do institutionals & insiders hold more shares of OMGA or CRVO? 97.5% of Omega Therapeutics shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 8.5% of Omega Therapeutics shares are held by company insiders. Comparatively, 36.3% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryCervoMed beats Omega Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Wall Street StarHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVO vs. The Competition Export to ExcelMetricCervoMedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.97M$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E RatioN/A10.79135.4217.51Price / Sales1.68286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book1.495.404.894.94Net Income-$2.17M$152.04M$118.71M$225.59M7 Day Performance-0.51%-4.19%15.74%-1.07%1 Month Performance-81.36%2.70%15.70%7.23%1 Year Performance-75.16%17.16%34.85%22.97% CervoMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVOCervoMed2.5104 of 5 stars$1.94flat$42.00+2,064.9%-77.2%$11.97M$7.14M0.004Analyst DowngradeGap DownOMGAOmega Therapeutics2.316 of 5 stars$0.86-11.2%$9.20+969.8%-65.3%$47.62M$3.09M0.00120CDIOCardio Diagnostics2.5347 of 5 stars$1.17-7.1%$2.00+70.9%-63.7%$47.32M$35,688.000.007News CoverageGap DownHigh Trading VolumeBIVIBioVie0.8249 of 5 stars$2.66+0.8%$3.00+12.8%+71.7%$47.26MN/A-0.2310ACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/AN/A$47.14MN/A0.004High Trading VolumeALRNAileron Therapeutics3.8079 of 5 stars$2.16-4.4%$19.00+779.6%-49.5%$46.81MN/A-0.729Positive NewsVIRIVirios Therapeutics1.4262 of 5 stars$2.36-2.1%$3.00+27.1%+249.5%$45.45MN/A-8.745Gap DownICCCImmuCell0.7724 of 5 stars$4.96+0.8%N/A+5.9%$44.20M$23.84M-9.8475Positive NewsGap DownDYAIDyadic International1.7249 of 5 stars$1.49-8.6%$6.00+302.7%-8.8%$44.09M$3.36M-7.097Gap DownPASGPassage Bio2.9793 of 5 stars$0.71-6.3%$7.75+990.2%-10.7%$43.91MN/A0.00130ESLAEstrella Immunopharma0.4528 of 5 stars$1.19-0.3%N/A-2.4%$43.06MN/A-4.50N/AGap Up Related Companies and Tools Related Companies OMGA Alternatives CDIO Alternatives BIVI Alternatives ACAB Alternatives ALRN Alternatives VIRI Alternatives ICCC Alternatives DYAI Alternatives PASG Alternatives ESLA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRVO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
